Completed OBSERVATIONAL NCT01158183

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis

Sponsor: Bayer

Conditions Multiple Sclerosis, Relapsing-Remitting

Interventions BAY86-5046_Interferon-beta-1b

Updated 5 times since 2017 Last updated: Jul 7, 2010 Started: Jul 31, 2007 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Multiple Sclerosis, Relapsing-Remitting and is currently completed. Bayer leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Many Locations, United States